Utilizing Predictive Inflammatory Markers for Guiding the Use of Biologicals in Severe Asthma

References

• Hekking P-PW, Wener RR, Amelink M, et al. The prevalence of severe refractory asthma. J Allergy Clin Immunol. 2015;135(4):896–902. doi:10.1016/j.jaci.2014.08.042
   PubMed Web of Science ®Google Scholar
• Kuruvilla ME, Lee FE, Lee GB. Understanding asthma phenotypes, endotypes, and mechanisms of disease. Clin Rev Allergy Immunol. 2019;56(2):219–233. doi:10.1007/s12016-018-8712-1
   PubMed Web of Science ®Google Scholar
• Akar-Ghibril N, Casale T, Custovic A, et al. Allergic endotypes and phenotypes of asthma. J Allergy Clin Immunol Pract. 2020;8(2):429–440. doi:10.1016/j.jaip.2019.11.008
   PubMed Web of Science ®Google Scholar
• Fitzpatrick AM, Chipps BE, Holguin F, et al. T2-”Low” asthma: overview and management strategies. J Allergy Clin Immunol Pract. 2020;8(2):452–463. doi:10.1016/j.jaip.2019.11.006
   PubMed Web of Science ®Google Scholar
• Hanania NA, Alpan O, Hamilos DL, et al. Omalizumab in severe allergic asthma inadequately controlled with standard therapy: a randomized trial. Ann Intern Med. 2011;154(9):573–582. doi:10.7326/0003-4819-154-9-201105030-00002
   PubMed Web of Science ®Google Scholar
• Lim H, Nair P. Airway inflammation and inflammatory biomarkers. Semin Respir Crit Care Med. 2018;39(01):056–063. doi:10.1055/s-0037-1606217
   PubMed Web of Science ®Google Scholar
• Korevaar DA, Westerhof GA, Wang J, et al. Diagnostic accuracy of minimally invasive markers for detection of airway eosinophilia in asthma: a systematic review and meta-analysis. Lancet Respir Med. 2015;3(4):290–300. doi:10.1016/S2213-2600(15)00050-8
   PubMed Web of Science ®Google Scholar
• Boulet LP, Reddel HK, Bateman E, et al. The Global Initiative for Asthma (GINA): 25 years later. Eur Respir J. 2019;54(2):1900598. doi:10.1183/13993003.00598-2019
   PubMed Web of Science ®Google Scholar
• Peters MC, Wenzel SE. Intersection of biology and therapeutics: type 2 targeted therapeutics for adult asthma. Lancet. 2020;395(10221):371–383. doi:10.1016/S0140-6736(19)33005-3
   PubMed Web of Science ®Google Scholar
• Corren J, Du E, Gubbi A, et al. Variability in blood eosinophil counts in patients with eosinophilic asthma. J Allergy Clin Immunol Pract. 2021;9(3):1224–1231 e9. doi:10.1016/j.jaip.2020.10.033
   PubMed Web of Science ®Google Scholar
• Ortega H, Gleich G, Mayer B, et al. Reproducibility of a single blood eosinophil measurement as a biomarker in severe eosinophilic asthma. Ann Am Thorac Soc. 2015;12(12):1896–1897. doi:10.1513/AnnalsATS.201507-443LE
   PubMed Web of Science ®Google Scholar
• McGregor MC, Krings JG, Nair P, et al. Role of biologics in asthma. Am J Respir Crit Care Med. 2019;199(4):433–445. doi:10.1164/rccm.201810-1944CI
   PubMed Web of Science ®Google Scholar
• Ortega HG, Liu MC, Pavord ID, et al. Mepolizumab treatment in patients with severe eosinophilic asthma. N Engl J Med. 2014;371(13):1198–1207. doi:10.1056/NEJMoa1403290
   PubMed Web of Science ®Google Scholar
• Ortega HG, Yancey SW, Mayer B, et al. Severe eosinophilic asthma treated with mepolizumab stratified by baseline eosinophil thresholds: a secondary analysis of the DREAM and MENSA studies. Lancet Respir Med. 2016;4(7):549–556. doi:10.1016/S2213-2600(16)30031-5
   PubMed Web of Science ®Google Scholar
• Albers FC, Licskai C, Chanez P, et al. Baseline blood eosinophil count as a predictor of treatment response to the licensed dose of mepolizumab in severe eosinophilic asthma. Respir Med. 2019;159:105806. doi:10.1016/j.rmed.2019.105806
   PubMed Web of Science ®Google Scholar
• Corren J, Weinstein S, Janka L, et al. Phase 3 study of reslizumab in patients with poorly controlled asthma: effects across a broad range of eosinophil counts. Chest. 2016;150(4):799–810. doi:10.1016/j.chest.2016.03.018
   PubMed Web of Science ®Google Scholar
• Bleecker ER, Wechsler ME, FitzGerald JM, et al. Baseline patient factors impact on the clinical efficacy of benralizumab for severe asthma. Eur Respir J. 2018;52(4):1800936. doi:10.1183/13993003.00936-2018
   PubMed Web of Science ®Google Scholar
• Rabe KF, Nair P, Brusselle G, et al. Efficacy and safety of dupilumab in glucocorticoid-dependent severe asthma. N Engl J Med. 2018;378(26):2475–2485. doi:10.1056/NEJMoa1804093
   PubMed Web of Science ®Google Scholar
• Castro M, Corren J, Pavord ID, et al. Dupilumab efficacy and safety in moderate-to-severe uncontrolled asthma. N Engl J Med. 2018;378(26):2486–2496. doi:10.1056/NEJMoa1804092
   PubMed Web of Science ®Google Scholar
• Hanania NA, Wenzel S, Rosén K, et al. Exploring the effects of omalizumab in allergic asthma: an analysis of biomarkers in the EXTRA study. Am J Respir Crit Care Med. 2013;187(8):804–811. doi:10.1164/rccm.201208-1414OC
   PubMed Web of Science ®Google Scholar
• Humbert M, Taillé C, Mala L, et al. Omalizumab effectiveness in patients with severe allergic asthma according to blood eosinophil count: the STELLAIR study. Eur Respir J. 2018;51(5):1702523. doi:10.1183/13993003.02523-2017
   PubMed Web of Science ®Google Scholar
• Casale TB, Luskin AT, Busse W, et al. Omalizumab effectiveness by biomarker status in patients with asthma: evidence from PROSPERO, A prospective real-world study. J Allergy Clin Immunol Pract. 2019;7(1):156–164 e1. doi:10.1016/j.jaip.2018.04.043
   PubMed Web of Science ®Google Scholar
• Nair P, Wenzel S, Rabe KF, et al. Oral glucocorticoid-sparing effect of benralizumab in severe asthma. N Engl J Med. 2017;376(25):2448–2458. doi:10.1056/NEJMoa1703501
   PubMed Web of Science ®Google Scholar
• Mukherjee M, Forero, DF, Tran S, et al. Suboptimal treatment response to anti-IL-5 monoclonal antibodies in severe eosinophilic asthmatics with airway autoimmune phenomena. Eur Respir J. 2020;56(4):2000117. doi:10.1183/13993003.00117-2020
   PubMed Web of Science ®Google Scholar
• Price DB, Rigazio A, Campbell JD, et al. Blood eosinophil count and prospective annual asthma disease burden: a UK cohort study. Lancet Respir Med. 2015;3(11):849–858. doi:10.1016/S2213-2600(15)00367-7
   PubMed Web of Science ®Google Scholar
• Busse WW. Biological treatments for severe asthma: a major advance in asthma care. Allergol Int. 2019;68(2):158–166. doi:10.1016/j.alit.2019.01.004
   PubMedGoogle Scholar
• Hastie AT, Moore WC, Li H, et al. Biomarker surrogates do not accurately predict sputum eosinophil and neutrophil percentages in asthmatic subjects. J Allergy Clin Immunol. 2013;132(1):72–80. doi:10.1016/j.jaci.2013.03.044
   PubMed Web of Science ®Google Scholar
• Wagener AH, de Nijs SB, Lutter R, et al. External validation of blood eosinophils, FE(NO) and serum periostin as surrogates for sputum eosinophils in asthma. Thorax. 2015;70(2):115–120. doi:10.1136/thoraxjnl-2014-205634
   PubMed Web of Science ®Google Scholar
• Zhang X-Y, Simpson JL, Powell H, et al. Full blood count parameters for the detection of asthma inflammatory phenotypes. Clin Exp Allergy. 2014;44(9):1137–1145. doi:10.1111/cea.12345
   PubMed Web of Science ®Google Scholar
• Lugogo N, Green CL, Agada N, et al. Obesity’s effect on asthma extends to diagnostic criteria. J Allergy Clin Immunol. 2018;141(3):1096–1104. doi:10.1016/j.jaci.2017.04.047
   PubMed Web of Science ®Google Scholar
• Fahy JV. Type 2 inflammation in asthma–present in most, absent in many. Nat Rev Immunol. 2015;15(1):57–65. doi:10.1038/nri3786
   PubMed Web of Science ®Google Scholar
• Nelson RK, Bush A, Stokes J, et al. Eosinophilic Asthma. J Allergy Clin Immunol Pract. 2020;8(2):465–473. doi:10.1016/j.jaip.2019.11.024
   PubMed Web of Science ®Google Scholar
• Denlinger LC, Phillips BR, Ramratnam S, et al. Inflammatory and Comorbid Features of Patients with Severe Asthma and Frequent Exacerbations. Am J Respir Crit Care Med. 2017;195(3):302–313. doi:10.1164/rccm.201602-0419OC
   PubMed Web of Science ®Google Scholar
• Katz LE, Gleich GJ, Hartley BF, et al. Blood eosinophil count is a useful biomarker to identify patients with severe eosinophilic asthma. Ann Am Thorac Soc. 2014;11(4):531–536. doi:10.1513/AnnalsATS.201310-354OC
   PubMedGoogle Scholar
• Nair P, Pizzichini MMM, Kjarsgaard M, et al. Mepolizumab for prednisone-dependent asthma with sputum eosinophilia. N Engl J Med. 2009;360(10):985–993. doi:10.1056/NEJMoa0805435
   PubMed Web of Science ®Google Scholar
• Haldar P, Brightling CE, Hargadon B, et al. Mepolizumab and exacerbations of refractory eosinophilic asthma. N Engl J Med. 2009;360(10):973–984. doi:10.1056/NEJMoa0808991
   PubMed Web of Science ®Google Scholar
• Mukherjee M, Aleman Paramo F, Kjarsgaard M, et al. Weight-adjusted Intravenous Reslizumab in Severe Asthma with Inadequate Response to Fixed-Dose Subcutaneous Mepolizumab. Am J Respir Crit Care Med. 2018;197(1):38–46. doi:10.1164/rccm.201707-1323OC
   PubMed Web of Science ®Google Scholar
• Bhalla A, Zhao N, Rivas DD, et al. Exacerbations of Severe Asthma While on Anti-IL-5 Biologics. J Investig Allergol Clin Immunol. 2020;30(5):307–316. doi:10.18176/jiaci.0628
   PubMed Web of Science ®Google Scholar
• Djukanovic R, Wilson SJ, Kraft M, et al. Effects of treatment with anti-immunoglobulin E antibody omalizumab on airway inflammation in allergic asthma. Am J Respir Crit Care Med. 2004;170(6):583–593. doi:10.1164/rccm.200312-1651OC
   PubMed Web of Science ®Google Scholar
• Kharitonov SA, Gonio F, Kelly C, et al. Reproducibility of exhaled nitric oxide measurements in healthy and asthmatic adults and children. Eur Respir J. 2003;21(3):433–438. doi:10.1183/09031936.03.00066903a
   PubMed Web of Science ®Google Scholar
• Ledford D, Busse W, Trzaskoma B, et al. A randomized multicenter study evaluating Xolair persistence of response after long-term therapy. J Allergy Clin Immunol. 2017;140(1):162–169 e2. doi:10.1016/j.jaci.2016.08.054
   PubMed Web of Science ®Google Scholar
• Pavord ID, Korn S, Howarth P, et al. Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial. Lancet. 2012;380(9842):651–659. doi:10.1016/S0140-6736(12)60988-X
   PubMed Web of Science ®Google Scholar
• Hearn AP, Kavanagh J, d’Ancona G, et al. The relationship between Feno and effectiveness of mepolizumab and benralizumab in severe eosinophilic asthma. J Allergy Clin Immunol Pract. 2021;9(5):2093–2096 e1. doi:10.1016/j.jaip.2021.01.008
   PubMed Web of Science ®Google Scholar
• Ramonell RP, Lee FE-H, Levy JM, et al. Exhaled nitric oxide measurements are not influenced by anti-eosinophil therapy in patients with asthma: a retrospective analysis. Ann Allergy Asthma Immunol. 2021;126(1):102–104. doi:10.1016/j.anai.2020.09.005
   PubMed Web of Science ®Google Scholar
• Beeh KM, Ksoll M, Buhl R. Elevation of total serum immunoglobulin E is associated with asthma in nonallergic individuals. Eur Respir J. 2000;16(4):609–614. doi:10.1034/j.1399-3003.2000.16d07.x
   PubMed Web of Science ®Google Scholar
• Bachert C, Humbert M, Hanania NA, et al. Staphylococcus aureus and its IgE-inducing enterotoxins in asthma: current knowledge. Eur Respir J. 2020;55(4):1901592. doi:10.1183/13993003.01592-2019
   PubMed Web of Science ®Google Scholar
• Mouthuy J, Detry B, Sohy C, et al. Presence in sputum of functional dust mite-specific IgE antibodies in intrinsic asthma. Am J Respir Crit Care Med. 2011;184(2):206–214. doi:10.1164/rccm.201009-1434OC
   PubMed Web of Science ®Google Scholar
• Bousquet J, Cabrera P, Berkman N, et al. The effect of treatment with omalizumab, an anti-IgE antibody, on asthma exacerbations and emergency medical visits in patients with severe persistent asthma. Allergy. 2005;60(3):302–308. doi:10.1111/j.1398-9995.2004.00770.x
   PubMed Web of Science ®Google Scholar
• Pillai P, Chan Y-C, Wu S-Y, et al. Omalizumab reduces bronchial mucosal IgE and improves lung function in non-atopic asthma. Eur Respir J. 2016;48(6):1593–1601. doi:10.1183/13993003.01501-2015
   PubMed Web of Science ®Google Scholar
• Corren J, Castro M, O’Riordan T, et al. Dupilumab Efficacy in Patients with Uncontrolled, Moderate-to-Severe Allergic Asthma. J Allergy Clin Immunol Pract. 2020;8(2):516–526. doi:10.1016/j.jaip.2019.08.050
   PubMed Web of Science ®Google Scholar
• Ortega H, Chupp G, Bardin P, et al. The role of mepolizumab in atopic and nonatopic severe asthma with persistent eosinophilia. Eur Respir J. 2014;44(1):239–241. doi:10.1183/09031936.00220413
   PubMed Web of Science ®Google Scholar
• Chipps BE, Newbold P, Hirsch I, Trudo F, Goldman M. Benralizumab efficacy by atopy status and serum immunoglobulin E for patients with severe, uncontrolled asthma. Ann Allergy Asthma Immunol. 2018;120(5):504–511 e4. doi:10.1016/j.anai.2018.01.030
   PubMed Web of Science ®Google Scholar
• Tajiri T, Matsumoto H, Gon Y, et al. Utility of serum periostin and free IgE levels in evaluating responsiveness to omalizumab in patients with severe asthma. Allergy. 2016;71(10):1472–1479. doi:10.1111/all.12922
   PubMed Web of Science ®Google Scholar
• Hamilton JD, Harel S, Swanson BN, et al. Dupilumab suppresses type 2 inflammatory biomarkers across multiple atopic, allergic diseases. Clin Exp Allergy. 2021;51(7):915–931. doi:10.1111/cea.13954
   PubMed Web of Science ®Google Scholar
• Izuhara K, Ohta S, Ono J. Using periostin as a biomarker in the treatment of asthma. Allergy Asthma Immunol Res. 2016;8(6):491–498. doi:10.4168/aair.2016.8.6.491
   PubMed Web of Science ®Google Scholar
• Heaney LG, Djukanovic R, Woodcock A, et al. Research in progress: medical Research Council United Kingdom Refractory Asthma Stratification Programme (RASP-UK). Thorax. 2016;71(2):187–189. doi:10.1136/thoraxjnl-2015-207326
   PubMed Web of Science ®Google Scholar
• Pettipher R, Hunter MG, Perkins CM, et al. Heightened response of eosinophilic asthmatic patients to the CRTH2 antagonist OC000459. Allergy. 2014;69(9):1223–1232. doi:10.1111/all.12451
   PubMed Web of Science ®Google Scholar
• Menzies-Gow A, Corren J, Bourdin A, et al. Tezepelumab in Adults and Adolescents with Severe, Uncontrolled Asthma. N Engl J Med. 2021;13;384(19):1800–1809.
   Google Scholar